Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Adoptive cell therapy with T cells genetically engineered to express a chimeric antigen receptor (CAR-T) or tumor-infiltrating T lymphocytes (TIL) demonstrates impressive clinical results in patients with cancer. Lymphodepleting preconditioning prior to cell infusion is an integral part of all adoptive T cell therapies. However, to date, there is no standardization and no data comparing different non-myeloablative (NMA) regimens.

Related collections

Most cited references 39

Record: found
Abstract: found
Article: not found

Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma.

Bo Hu, Xin-Rong Yang, Yang Xu … (2014)

We developed a novel systemic immune-inflammation index (SII) based on lymphocyte, neutrophil, and platelet counts and explored its prognostic value in hepatocellular carcinoma (HCC).

0 comments Cited 605 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Is Open Access

Systemic immune-inflammation index for predicting prognosis of colorectal cancer

Jian-Hui Chen, Er-Tao Zhai, Yu-Jie Yuan … (2017)

AIM To investigate the clinical significance of preoperative systemic immune-inflammation index (SII) in patients with colorectal cancer (CRC). METHODS A retrospective analysis of 1383 cases with CRC was performed following radical surgery. SII was calculated with the formula SII = (P × N)/L, where P, N, and L refer to peripheral platelet, neutrophil, and lymphocyte counts, respectively. The clinicopathological features and follow-up data were evaluated to compare SII with other systemic inflammation-based prognostic indices such as the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in patients with CRC. RESULTS The optimal cut-off point for SII was defined as 340. The overall survival (OS) and disease-free survival (DFS) were better in patients with low NLR, PLR, and SII (P < 0.05). The SII was an independent predictor of OS and DFS in multivariate analysis. The area under the receiver-operating characteristics (ROC) curve for SII (0.707) was larger than those for NLR (0.602) and PLR (0.566). In contrast to NLR and PLR, SII could effectively discriminate between the TNM subgroups. CONCLUSION SII is a more powerful tool for predicting survival outcome in patients with CRC. It might assist the identification of high-risk patients among patients with the same TNM stage.

0 comments Cited 267 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

R. Wunderlich, Susan Morton, John Dudley … (2002)

We report here the adoptive transfer, to patients with metastatic melanoma, of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a nonmyeloablative conditioning regimen. This approach resulted in the persistent clonal repopulation of T cells in those cancer patients, with the transferred cells proliferating in vivo, displaying functional activity, and trafficking to tumor sites. This led to regression of the patients' metastatic melanoma as well as to the onset of autoimmune melanocyte destruction. This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases.

0 comments Cited 185 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (iso-abbrev): J Immunother Cancer

Title: Journal for immunotherapy of cancer

Publisher: BMJ

ISSN (Electronic): 2051-1426

ISSN (Print): 2051-1426

Publication date (Electronic): May 2021

Volume: 9

Issue: 5

Affiliations

[1 ] Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel.

[2 ] Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.

[3 ] Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel.

[4 ] Department of Hematology, Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel.

[5 ] Oncology Division, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel.

[6 ] Deparment of Clinical Microbiology and Immunology, Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel.

[7 ] Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel Michal.Besser@sheba.health.gov.il.

Article

Publisher Item ID: jitc-2020-001743

DOI: 10.1136/jitc-2020-001743

PMC ID: 8127974

PubMed ID: 33990415

SO-VID: 102dbd9f-2f54-419c-8961-e97a650286c7

History

Keywords: tumor-infiltrating,adoptive,chimeric antigen,receptors,clinical trials,immunotherapy,lymphocytes,phase II as topic

Data availability:

Keywords: tumor-infiltrating, adoptive, chimeric antigen, receptors, clinical trials, immunotherapy, lymphocytes, phase II as topic

Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy.

Read this article at

Abstract

Related collections

Regulatory T cell (Treg) therapy

Most cited references 39

Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma.

Systemic immune-inflammation index for predicting prognosis of colorectal cancer

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 238

Cited by 16